The CR Rate Is 50% in P53 Mutant Patients Compared to HMA Venn

The CR rate is 50% but about the same in p53 mutant patients as it is in p53 wild type we again whether the response rates could translate into a long term better long term survival is really the issue. recovery wasn't prolonged by the use of McGrollumab and in those who respond about two thirds of them do so at Mardee negative by flow cytometry. The company that owns this drug is doing two trials one is called the enhanced to trial of a ZVN versus a ZVM McGroll and p53 mutant patient group than HMA Venn which seems like according to a log ring test AVM was a bit better in terms of survival in this p